Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2014

Open Access 01-12-2014 | Editorial

SEOM guidelines 2014: improving quality to increase its usefulness

Authors: P. Garrido, C. A. Rodríguez

Published in: Clinical and Translational Oncology | Issue 12/2014

Login to get access

Excerpt

Since 2010, when the Spanish Society for Medical Oncology (SEOM) started publishing clinical practice guidelines for the management of solid tumours and supportive care, the challenges have evolved from educational purposes to policy purposes. Due to our increasingly complex system, patient care requires cohesive documents on which to base daily decisions [1‐3] and SEOM is really committed to working on balancing both sustainability and equity in the access to new treatment options. …
Literature
1.
2.
Isla D, González A, Alba E. The relevance of Spanish society for medical oncology (SEOM) clinical oncology guidelines. Clin Transl Oncol. 2010;12(11):707–8.CrossRef
3.
Rodriguez CA, Cruz-Hernández JJ. SEOM guidelines 2013: a response to the needs of Spanish oncologists. Clin Transl Oncol. 2013;15(12):975–6.PubMedCrossRef
4.
Cruz-Hernandez JJ, Rodríguez CA. SEOM clinical guidelines: a consolidated project. Clin Transl Oncol. 2012;14(7):489–90.PubMedCrossRef
5.
6.
7.
Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1238-y.
8.
Cassinello J, Climent MA, González del Alba A, Mellado B, Virizuela JA. SEOM Clinical guidelines for the treatment of metastatic prostate cancer. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1225-3.
9.
Bellmunt J, Puente J, Garcia de Muro J, Lainez N, Rodríguez C, Duran I. SEOM clinical guidelines for the treatment of renal cell carcinoma. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1219-1.
10.
Garcia-Carbonero R, JImenez-Fonseca P, Teulé A, Barriuso J, Sevilla I. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1214-6.
11.
12.
13.
Martín RC, Palomo AG, de la Cruz Merino L, García PB, Duarte FJB. Clinical guideline SEOM: cancer of unknown primary site. Clin Transl Oncol. 2014. doi:10.​1007/​s12094-014-1244-0.
Metadata
Title
SEOM guidelines 2014: improving quality to increase its usefulness
Authors
P. Garrido
C. A. Rodríguez
Publication date
01-12-2014
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2014
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-014-1246-y

Other articles of this Issue 12/2014

Clinical and Translational Oncology 12/2014 Go to the issue

Clinical Guides in Oncology

Thyroid cancer: SEOM clinical guidelines

Clinical Guides in Oncology

SEOM clinical guidelines for the treatment of renal cell carcinoma

Clinical Guides in Oncology

SEOM guide to primary and secondary prevention of cancer: 2014

Clinical Guides in Oncology

Clinical guideline SEOM: cancer of unknown primary site

Clinical Guides in Oncology

SEOM guidelines on hydroelectrolytic disorders

Clinical Guides in Oncology

SEOM Clinical guidelines for the treatment of metastatic prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits